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1. Introduction 
Cardiovascular diseases still represent the leading cause of death in the western world. 
Coronary artery disease (CAD) affects over 5% of the US population and is responsible for 
nearly 7 millions of in-patient procedures every year (1). Peripheral arterial disease (PAD), 
with a prevalence of 3-30%, also is a very common disease (2). PAD can be classified 
according to the severity of clinical symptoms into Fontaine-stages I-IV. In Fontaine-stage I 
patients are clinically asymptomatic and this stage is the most common form of PAD (70-
80%). Patients with Fontaine II (10-20%) suffer from intermittent claudication that might be 
life-style limiting and require therapy like percutaneous transluminal angioplasty (PTA). A 
smaller portion (3-5%) of PAD patients have critical limb ischemia (CLI) characterized by 
rest pain (Fontaine III) or ulcer (Fontaine IV). The incidence of CLI is estimated to be 500-
1000 per 1 Million but prognosis is very bad. One year after diagnosis only 45 % of patients 
are alive without major amputation and effective revascularization with relieve of 
symptoms can only be achieved in 25% of patients. Therefore, new therapeutic strategies are 
urgently needed for these patients.  
2. Preclinical data 
Generation of new blood vessels can be achieved by sprouting of new vessels out of the pre-
existing capillary plexus (angiogenesis), by generation of new arteries (arteriogenesis) or by 
circulating endothelial progenitor cells (vasculogenesis) (3). Several factors have been 
characterized which induce growth of new blood vessels, the most prominent being 
vascular endothelial growth factor (VEGF) and members of the fibroblast growth factor 
(FGF) family. In animal models of hindlimb and myocardial ischemia beneficial effects on 
blood perfusion and blood vessel density of these (and other) factors as well as of progenitor 
cells could be demonstrated (4) (5). This therapeutic concept was named “therapeutic 
angiogenesis“ and application of angiogenic factors via gene therapy vectors like plasmids 
or adenoviruses was superior to protein application probably due to longer lasting 
expression of respective cytokines. 
3. Therapeutic angiogenesis: gene therapy trials in PAD patients 
Due to promising data in preclinical studies the concept of therapeutic angiogenesis was 
tested in clinical trials in PAD and CAD patients. While first phase-1 studies in PAD patients 
were promising phase-II studies in patients with intermittent claudication were negative 
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(see summary for clinical trials in PAD patients in table 1). Obviously especially patients 
with CLI respond to therapy with angiogenic factors and gene therapy seems to have a 
benefit over therapy with respective proteins. 
 
Trial Factor Patients Effects Reference 
Phase-1 VEGF-165 
plasmid i.m. 
n=6; CLI 
(Buerger’s) 
Increase ABI, 
collaterals; 
improvement 
ulcer, pain 
Isner et al 1998 
(6) 
Phase-1 VEGF-165 
plasmid i.m. 
n=9;  
CLI 
Increase ABI, 
collaterals; 
improvement 
ulcer, pain, 
walking time 
Baumgartner et 
al 1998 (7) 
PREVENT I 
Phase-1 
E2F decoy, 
bypass graft 
ex-vivo  
n=41; bypass 
OP 
Reduction bypass-
stenosis, -
occlusion and -
revision 
Mann et al 1999 
(8) 
Phase-1 FGF-2 protein 
i.a. 
n=13; 
claudication 
Increase calf 
blood flow 
Lazarous et al 
2000 (9) 
Phase-1 FGF-2 protein 
i.v. 
n=24; 
claudication 
No improvement 
of walking time, 
proteinuria 
Cooper et al 
2001(10) 
Phase-1 FGF-1 Plasmid 
i.m. 
n=66; 
CLI 
Improvement 
TcPO2, ABI, pain, 
ulcer 
Comerota et al 
2002 (11) 
TRAFFIC 
Phase-2 
FGF-2 protein 
i.a. 
n=195; 
claudication 
Improvement 
walking time, ABI 
day 90, not 180  
Lederman et al 
2002 (12) 
RAVE 
Phase-2 
VEGF-121 
adenovirus 
i.m. 
n=105; 
claudication 
No improvement 
of walking time 
Rajagopalan et al 
2003 (13) 
Phase-1 VEGF-165 
plasmid i.m. 
n=21; 
CLI 
Improvement 
ABI, collaterals, 
ulcer, pain  
Shyu et al 2003 
(14) 
Phase-1/2 FGF-4 
adenovirus 
i.m. 
n=13, 
CLI 
Improvement 
pain 
Matyas et al 
2005(15) 
PREVENT III 
Phase-3 
E2F decoy, 
bypass graft 
ex-vivo 
n=1138 
bypass 
operation 
Secondary bypass 
patency 
improved; 
primary endpoint 
(time to bypass 
occlusion) 
negative 
Conte et al 
2006(16) 
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Trial Factor Patients Effects Reference 
Phase-1/2 HGF plasmid 
i.m. 
n=6; 
CLI 
Improvement 
pain, ABI, TcPO2, 
ulcer 
Morishita et al 
2006(17) 
Phase-1/2 FGF-2 gelatine-
hydrogel 
n=7; 
CLI 
Improvement 
walking time, 
TcPO2, ABI, pain 
Marui et al 
2007(18) 
DELTA-1 
Phase-2 
Del-1 plasmid 
i.m. 
n=105; 
claudication 
No improvement 
walking time, ABI 
Grossman et al 
2007(19) 
Phase-1 HIF-1α/VP16 
adenovirus 
i.m. 
n=41; 
CLI 
Improvement 
pain, ulcer 
Rajagopalan et al 
2007(20) 
WALK 
Phase-2 
HIF-1α/VP16 
adenovirus 
i.m. 
n=289 
claudication 
No difference in 
walking time 
ACC 2009 
Abbreviations: CLI, critical limb ischemia; ABI, ankle/brachial index; E2F, transcription factor E2F; 
HGF, hepatocyte growth factor; Del-1, developmentally regulated endothelial locus 1; HIF-1 α, hypoxia 
inducible factor-1 α ; Buerger’s, thrombangitis obliterans Winiwater-Buerger; i.m., intra-muscular; i.v., 
intra-venous; i.a., intra-arterial; TcPO2, transcutaneous oxygen tension 
Table 1. Therapeutic angiogenesesis in PAD.  
 
Trial Factor Patients Outcome 
VEGF PVD 
Mäkinen et al (22) 
VEGF-165 adenovirus 
or plasmid/liposome 
i.a. after PTA 
n=54; 
claudication, 
CLI  
Increase of vascular 
density 
Groningen 
Kusumanto et al 
(23) 
VEGF-165 plasmid 
i.m. 
n=54; 
CLI 
Improvement ABI, 
ulcers 
TALISMAN 
Nikol et al (24) 
FGF-1 plasmid i.m. n=112;
CLI 
Reduction of 
amputations; primary 
endpoint (healing of 
ulcers) not reached 
HGF-STAT 
Powell et al (25) 
HGF plasmid i.m. n=106;
CLI 
Improvement TcPO2 
TAMARIS, Phase 3
AHA 2010 
FGF-1 plasmid i.m. n=525;
CLI 
Primary endpoint 
(major amputation or 
death) not reached 
Abbreviations: ABI, ankle/brachial index; i.m., intra-muscular; i.v., intra-venous; i.a., intra-arterial; 
TcPO2, transcutaneous oxygen tension 
Table 2. Therapeutic Angiogenesis in PAD:-larger placebo-controlled, double-blinded trials. 
The last years several placebo-controlled double-blinded trials have been published which 
showed beneficial effects in CLI patients after i.m.plasmid gene therapy with VEGF, FGF1 or 
hepatocyte growth factor (HGF) (Tab. 2). Especially the TALISMAN study could 
demonstrate a reduction in amputation rate. Regarding potential adverse effects these 
studies did not show evidence of increase of cancer rates or proliferative retinopathy. (21) 
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The positive results of the TALISMAN study on reduction of amputation rate and mortality 
in CLI patients by FGF1 gene therapy was the basis for a large phase 3 study. Over 500 CLI 
patients were treated with FGF1 gene therapy versus placebo. The primary outcome after 12 
months was a combined endpoint of major amputation above the ankle or death. The results 
of this trial, called TAMARIS, were presented at the AHA meeting, November 2010, in 
Chicago, USA. There was no difference in mortality and major amputation between FGF1 
gene therapy and placebo. Also secondary endpoints were not different and there was no 
increase in occurrence of malignant diseases or proliferative retinopathy. The difference 
between the positive results in phase 2 (TALISMAN) and negative results in phase 3 
(TAMARIS) were explained by a type-1 error (finding by chance) in the phase-2 study. It 
will be interesting to see the publication of the TAMARIS trial to further discuss the reasons 
for this negative trial and the different results of this trial and phase 2 TALISMAN. 
4. Therapeutic angiogenesis: gene therapy trials in CAD patients 
Several angiogenic cytokines (especially VEGF-A and FGF4) were tested in patients with 
severe chronic CAD in whom revascularization by angioplasty or bypass surgery was no 
further option and who suffered from severe angina and limited exercise tolerance (for 
recent excellent reviews please also see (26, 27). As observed in PAD-patients phase-1 and 
phase-2 studies showed feasibility of these therapies and signs of bioactivity. Specifically, 
gene therapy (adenovirus, administered intra-coronary) with FGF4 showed a trend toward 
increase in exercise time in the AGENT (Angiogenic Gene Therapy) trial and the subsequent 
phase-2 AGENT 2 trial showed reduction in reversible perfusion defect size (however not 
statistically significant due to one outlier in the placebo group). The phase-3 AGENT 3 and 
AGENT 4 trials were stopped early when an interim analysis of the AGENT 3 cohort 
indicated that the primary endpoint (change in exercise treadmill test after 12 weeks) was 
unlikely to differ between FGF4 and placebo. A pooled analysis of AGENT 3 and 4 however 
revealed that women and patients >65 years with severe angina had statistically significant 
improvement in angina class and exercise test. A subsequent gene therapy trial in women 
with CAD was stopped, apparently due to slow enrollment.  
Also VEGF gene therapy was tested in CAD patients in randomized studies. In the Kuopio 
Angiogenesis Trial (KAT) no difference in restenosis rate (primary endpoint) was observed 
after intra-coronary VEGF gene therapy (plasmid liposome or adenovirus), however after 6 
months increased myocardial perfusion was found after adenoviral VEGF application. In 
the Euroinject One study VEGF plasmid was injected intra- myocardial into regions with 
perfusion defects. The primary endpoint, improvement of myocardial perfusion was not 
reached, however, VEGF improved regional wall motion score. 
For summary of controlled trials on therapeutic angiogenesis in CAD patients see table 3. 
5. Future perspectives 
The negative results of phase-3 trials AGENT and TAMARIS raise important question about 
therapeutic angiogenesis and gene therapy. What is the reason that therapeutic angiogenesis 
with factors like VEGF or FGF did improve outcomes in a variety of animal models but 
failed to improve human disease?  One explanation is that often young animals were used 
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Trial Factor Patients Effects Reference 
Phase-1/2 
VEGF-2 plasmid 
i.myoc. 
n=19; 
CCS3-4, 
RA, NR 
Improvement 
angina class 
Losordo et al 
2002(28) 
AGENT  
Phase-1/2 
Adenovirus-FGF4; 
i.coro. 
n=79;  
CCS2-3 
Trend toward 
increase in 
exercise time 
Grines et al 
2002 (29) 
AGENT 2 
Phase-2 
Adenovirus-FGF4; 
i.coro. 
n=52; 
CCS2-4, 
RA, NR 
Improvement of 
perfusion defects 
by SPECT (not 
sign.) 
Grines et al 
2003 (30) 
VIVA 
Phase-2 
VEGF protein 
i.coro., i.v. 
n=178;   
RA, NR 
Improvement 
angina class, no 
effect on exercise 
time 
Henry et al 
2003(31) 
KAT 
Phase-2 
VEGF-165 
adenovirus or 
plasmid/liposome 
i.coro. 
n=103; 
stable 
angina 
Improvement in 
myocardial 
perfusion, no 
effect on 
restenosis 
Hedman et al 
2003(32) 
EUROINJECT-
ONE 
Phase-2 
VEGF-165 Plasmid 
i.myoc. 
n=80; 
CCS3-4, 
RA, NR 
Improvement 
wall motion, no 
effect on 
myocardial 
perfusion 
Kastrup et al 
2005(33) 
REVASC 
Open label  
Adenovirus VEGF-
121 i.myoc. 
(thoracotomy) 
n=65; 
CCS2-4, 
RA, NR 
Improvement in 
exercise time at 
26 weeks, not at 
12 weeks  
Stewart et al 
2006(34) 
AGENT3/4 
Phase-3 
Adenovirus-FGF4; 
i.coro. 
n=532; 
CCS2-4, 
RA,  
(AGENT4: 
NR) 
Enrollment 
stopped after 
interim analysis, 
primary 
endpoint 
negative. 
Improvement 
angina and 
exercise time in 
women, older 
patients with 
severe 
symptoms 
Henry et al 
2007(35) 
Abbreviations: CCS, Canadian cardiovascular society;  i.coro., intra-coronary; i.myoc., intra-myocardial; 
i.v., intra-venous; NR, nonrevascularizable; RA, refractory stable angina; 
Table 3. Controlled trials on therapeutic angiogenesis in CAD patients. 
www.intechopen.com
 Gene Therapy - Developments and Future Perspectives 
 
294 
whereas in humans usually patients of older age and a variety of co-morbidities are affected. 
Additionally, transfection efficacy of gene therapy vectors, even of adenoviruses, is lower in 
humans than in animals and precise dosing of vectors is not possible due to the fact that 
transgene expression cannot be precisely quantified. Another open question is the selection 
of gene therapy vectors-adenoviruses usually have adverse effects, especially 
immunogenicity, whereas plasmid vectors are safe but have low transfection efficacy. Dose 
and duration of therapy is another question. One dose of a vector that expresses the 
transgene for days to weeks might not be sufficient to treat a disease that evolved over the 
time-course of many years. Also patient selection might have been a problem: usually “no-
option” patients were included in these studies, e.g. patients with large ischemic ulcers in 
the case of CLI (Rutherford class 6). Maybe patients with less severe disease, like patients 
with Rutherford class 5 or patients who would be treated additionally with 
revascularization procedures would benefit more from therapeutic angiogenesis. Endpoint 
selection is another critical point as some functional outcome measurements like severity of 
angina are subjective and might be affected by the placebo effect. Cell-based therapies have 
shown positive effects in CAD and PAD (36, 37)-maybe a combined therapeutic strategy 
consisting of cell application and gene therapy with angiogenic factors would result in 
better outcome.  
6. References 
[1] Nikol, S. 2008. Gene therapy of cardiovascular disease. Curr Opin Mol Ther 10:479- 
492. 
[2] Norgren, L., Hiatt, W.R., Dormandy, J.A., Nehler, M.R., Harris, K.A., Fowkes, F.G., Bell, 
K., Caporusso, J., Durand-Zaleski, I., Komori, K., et al. 2007. Inter-Society 
Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc 
Endovasc Surg 33 Suppl 1:S1-75. 
[3] Carmeliet, P. 2000. Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389- 
395. 
[4] Losordo, D.W., and Dimmeler, S. 2004. Therapeutic angiogenesis and vasculogenesis 
for ischemic disease: part I: angiogenic cytokines. Circulation 109:2487- 
2491. 
[5] Losordo, D.W., and Dimmeler, S. 2004. Therapeutic angiogenesis and vasculogenesis for 
ischemic disease: part II: cell-based therapies. Circulation 109:2692-2697. 
[6] Isner, J.M., Baumgartner, I., Rauh, G., Schainfeld, R., Blair, R., Manor, O., Razvi, S., and 
Symes, J.F. 1998. Treatment of thromboangiitis obliterans (Buerger's disease)  
by intramuscular gene transfer of vascular endothelial growth factor:  
preliminary clinical results. J Vasc Surg 28:964-973; discussion 973- 
965. 
[7] Baumgartner, I., Pieczek, A., Manor, O., Blair, R., Kearney, M., Walsh, K., and Isner, J.M. 
1998. Constitutive expression of phVEGF165 after intramuscular gene transfer 
promotes collateral vessel development in patients with critical limb ischemia. 
Circulation 97:1114-1123. 
www.intechopen.com
 Gene Therapy for Therapeutic Angiogenesis 
 
295 
[8] Mann, M.J., Whittemore, A.D., Donaldson, M.C., Belkin, M., Conte, M.S., Polak, J.F., 
Orav, E.J., Ehsan, A., Dell'Acqua, G., and Dzau, V.J. 1999. Ex-vivo gene therapy of 
human vascular bypass grafts with E2F decoy: the PREVENT single-centre, 
randomised, controlled trial. Lancet 354:1493-1498. 
[9] Lazarous, D.F., Unger, E.F., Epstein, S.E., Stine, A., Arevalo, J.L., Chew, E.Y., and 
Quyyumi, A.A. 2000. Basic fibroblast growth factor in patients with intermittent 
claudication: results of a phase I trial. Journal of the American College of Cardiology 
36:1339-1344. 
[10] Cooper, L.T., Jr., Hiatt, W.R., Creager, M.A., Regensteiner, J.G., Casscells, W., Isner, J.M., 
Cooke, J.P., and Hirsch, A.T. 2001. Proteinuria in a placebo-controlled study of 
basic fibroblast growth factor for intermittent claudication. Vasc Med 6:235- 
239. 
[11] Comerota, A.J., Throm, R.C., Miller, K.A., Henry, T., Chronos, N., Laird, J., Sequeira, R., 
Kent, C.K., Bacchetta, M., Goldman, C., et al. 2002. Naked plasmid DNA encoding 
fibroblast growth factor type 1 for the treatment of end-stage unreconstructible 
lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg 35:930-
936. 
[12] Lederman, R.J., Mendelsohn, F.O., Anderson, R.D., Saucedo, J.F., Tenaglia, A.N., 
Hermiller, J.B., Hillegass, W.B., Rocha-Singh, K., Moon, T.E., Whitehouse, M.J., et 
al. 2002. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for 
intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 359:2053-
2058. 
[13] Rajagopalan, S., Mohler, E.R., 3rd, Lederman, R.J., Mendelsohn, F.O., Saucedo, J.F., 
Goldman, C.K., Blebea, J., Macko, J., Kessler, P.D., Rasmussen, H.S., et al. 2003. 
Regional angiogenesis with vascular endothelial growth factor in peripheral 
arterial disease: a phase II randomized, double-blind, controlled study of 
adenoviral delivery of vascular endothelial growth factor 121 in patients with 
disabling intermittent claudication. Circulation 108:1933-1938. 
[14] Shyu, K.G., Chang, H., Wang, B.W., and Kuan, P. 2003. Intramuscular vascular 
endothelial growth factor gene therapy in patients with chronic critical leg 
ischemia. Am J Med 114:85-92. 
[15] Matyas, L., Schulte, K.L., Dormandy, J.A., Norgren, L., Sowade, O., Grotzbach, G., 
Palmer-Kazen, U., Rubanyi, G.M., and Wahlberg, E. 2005. Arteriogenic gene 
therapy in patients with unreconstructable critical limb ischemia: a randomized, 
placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-
4. Hum Gene Ther 16:1202-1211. 
[16] Conte, M.S., Bandyk, D.F., Clowes, A.W., Moneta, G.L., Seely, L., Lorenz, T.J., Namini, 
H., Hamdan, A.D., Roddy, S.P., Belkin, M., et al. 2006. Results of PREVENT III: a 
multicenter, randomized trial of edifoligide for the prevention of vein graft  
failure in lower extremity bypass surgery. J Vasc Surg 43:742-751;  
discussion 751. 
[17] Morishita, R., Aoki, M., Hashiya, N., Makino, H., Yamasaki, K., Azuma, J., Sawa, Y., 
Matsuda, H., Kaneda, Y., and Ogihara, T. 2004. Safety evaluation of clinical gene 
www.intechopen.com
 Gene Therapy - Developments and Future Perspectives 
 
296 
therapy using hepatocyte growth factor to treat peripheral arterial disease. 
Hypertension 44:203-209. 
[18] Marui, A., Tabata, Y., Kojima, S., Yamamoto, M., Tambara, K., Nishina, T., Saji, Y., Inui, 
K., Hashida, T., Yokoyama, S., et al. 2007. A novel approach to therapeutic 
angiogenesis for patients with critical limb ischemia by sustained release of basic 
fibroblast growth factor using biodegradable gelatin hydrogel: an initial report of 
the phase I-IIa study. Circ J 71:1181-1186. 
[19] Grossman, P.M., Mendelsohn, F., Henry, T.D., Hermiller, J.B., Litt, M., Saucedo, J.F., 
Weiss, R.J., Kandzari, D.E., Kleiman, N., Anderson, R.D., et al. 2007. Results from a 
phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for 
intermittent claudication in subjects with peripheral arterial disease. Am Heart J 
153:874-880. 
[20] Rajagopalan, S., Olin, J., Deitcher, S., Pieczek, A., Laird, J., Grossman, P.M., Goldman, 
C.K., McEllin, K., Kelly, R., and Chronos, N. 2007. Use of a constitutively active 
hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option 
critical limb ischemia patients: phase I dose-escalation experience. Circulation 
115:1234-1243. 
[21] Tongers, J., Roncalli, J.G., and Losordo, D.W. 2008. Therapeutic angiogenesis for critical 
limb ischemia: microvascular therapies coming of age. Circulation 118:9-16. 
[22] Makinen, K., Manninen, H., Hedman, M., Matsi, P., Mussalo, H., Alhava, E., and Yla-
Herttuala, S. 2002. Increased vascularity detected by digital subtraction 
angiography after VEGF gene transfer to human lower limb artery: a randomized, 
placebo-controlled, double-blinded phase II study. Mol Ther 6:127-133. 
[23] Kusumanto, Y.H., van Weel, V., Mulder, N.H., Smit, A.J., van den Dungen, J.J., 
Hooymans, J.M., Sluiter, W.J., Tio, R.A., Quax, P.H., Gans, R.O., et al. 2006. 
Treatment with intramuscular vascular endothelial growth factor gene compared 
with placebo for patients with diabetes mellitus and critical limb ischemia: a 
double-blind randomized trial. Hum Gene Ther 17:683-691. 
[24] Nikol, S., Baumgartner, I., Van Belle, E., Diehm, C., Visona, A., Capogrossi, M.C., 
Ferreira-Maldent, N., Gallino, A., Wyatt, M.G., Wijesinghe, L.D., et al. 2008. 
Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free 
survival in patients with critical limb ischemia. Mol Ther 16:972- 
978. 
[25] Powell, R.J., Simons, M., Mendelsohn, F.O., Daniel, G., Henry, T.D., Koga, M., 
Morishita, R., and Annex, B.H. 2008. Results of a double-blind, placebo-controlled 
study to assess the safety of intramuscular injection of hepatocyte growth factor 
plasmid to improve limb perfusion in patients with critical limb ischemia. 
Circulation 118:58-65. 
[26] Gupta, R., Tongers, J., and Losordo, D.W. 2009. Human studies of angiogenic gene 
therapy. Circ Res 105:724-736. 
[27] Beohar, N., Rapp, J., Pandya, S., and Losordo, D.W. 2010. Rebuilding the damaged 
heart: the potential of cytokines and growth factors in the treatment of ischemic 
heart disease. J Am Coll Cardiol 56:1287-1297. 
www.intechopen.com
 Gene Therapy for Therapeutic Angiogenesis 
 
297 
[28] Losordo, D.W., Vale, P.R., Hendel, R.C., Milliken, C.E., Fortuin, F.D., Cummings, N., 
Schatz, R.A., Asahara, T., Isner, J.M., and Kuntz, R.E. 2002. Phase 1/2 placebo-
controlled, double-blind, dose-escalating trial of myocardial vascular endothelial 
growth factor 2 gene transfer by catheter delivery in patients with chronic 
myocardial ischemia. Circulation 105:2012-2018. 
[29] Grines, C.L., Watkins, M.W., Helmer, G., Penny, W., Brinker, J., Marmur, J.D., West, A., 
Rade, J.J., Marrott, P., Hammond, H.K., et al. 2002. Angiogenic Gene Therapy 
(AGENT) trial in patients with stable angina pectoris. Circulation 105:1291- 
1297. 
[30] Grines, C.L., Watkins, M.W., Mahmarian, J.J., Iskandrian, A.E., Rade, J.J., Marrott, P., 
Pratt, C., and Kleiman, N. 2003. A randomized, double-blind, placebo-controlled 
trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients 
with stable angina. J Am Coll Cardiol 42:1339-1347. 
[31] Henry, T.D., Annex, B.H., McKendall, G.R., Azrin, M.A., Lopez, J.J., Giordano, F.J., 
Shah, P.K., Willerson, J.T., Benza, R.L., Berman, D.S., et al. 2003. The VIVA trial: 
Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. 
Circulation 107:1359-1365. 
[32] Hedman, M., Hartikainen, J., Syvanne, M., Stjernvall, J., Hedman, A., Kivela, A., 
Vanninen, E., Mussalo, H., Kauppila, E., Simula, S., et al. 2003. Safety and feasibility 
of catheter-based local intracoronary vascular endothelial growth factor  
gene transfer in the prevention of postangioplasty and in-stent restenosis and  
in the treatment of chronic myocardial ischemia: phase II results  
of the Kuopio Angiogenesis Trial (KAT). Circulation 107:2677- 
2683. 
[33] Kastrup, J., Jorgensen, E., Ruck, A., Tagil, K., Glogar, D., Ruzyllo, W., Botker, H.E., 
Dudek, D., Drvota, V., Hesse, B., et al. 2005. Direct intramyocardial  
plasmid vascular endothelial growth factor-A165 gene therapy in patients with 
stable severe angina pectoris A randomized double-blind placebo-controlled  
study: the Euroinject One trial. J Am Coll Cardiol 45:982- 
988. 
[34] Stewart, D.J., Hilton, J.D., Arnold, J.M., Gregoire, J., Rivard, A., Archer, S.L., 
Charbonneau, F., Cohen, E., Curtis, M., Buller, C.E., et al. 2006. Angiogenic gene 
therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 
randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum 
medical treatment. Gene Ther 13:1503-1511. 
[35] Henry, T.D., Grines, C.L., Watkins, M.W., Dib, N., Barbeau, G., Moreadith, R., 
Andrasfay, T., and Engler, R.L. 2007. Effects of Ad5FGF-4 in patients with angina: 
an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J Am Coll 
Cardiol 50:1038-1046. 
[36] Schachinger, V., Erbs, S., Elsasser, A., Haberbosch, W., Hambrecht, R., Holschermann, 
H., Yu, J., Corti, R., Mathey, D.G., Hamm, C.W., et al. 2006. Intracoronary bone 
marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 
355:1210-1221. 
www.intechopen.com
 Gene Therapy - Developments and Future Perspectives 
 
298 
[37] Walter, D.H., Krankenberg, H., Balzer, J.O., Kalka, C., Baumgartner, I., Schluter, M., 
Tonn, T., Seeger, F., Dimmeler, S., Lindhoff-Last, E., et al. 2011. Intraarterial 
Administration of Bone Marrow Mononuclear Cells in Patients With Critical Limb 
Ischemia: A Randomized-Start, Placebo-Controlled Pilot Trial (PROVASA). Circ 
Cardiovasc Interv 4:26-37. 
www.intechopen.com
Gene Therapy - Developments and Future Perspectives
Edited by Prof. Chunsheng Kang
ISBN 978-953-307-617-1
Hard cover, 356 pages
Publisher InTech
Published online 22, June, 2011
Published in print edition June, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The aim of this book is to cover key aspects of existing problems in the field of development and future
perspectives in gene therapy. Contributions consist of basic and translational research, as well as clinical
experiences, and they outline functional mechanisms, predictive approaches, patient-related studies and
upcoming challenges in this stimulating but also controversial field of gene therapy research. This source will
make our doctors become comfortable with the common problems of gene therapy and inspire others to delve
a bit more deeply into a topic of interest.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Rudolf Kirchmair (2011). Gene Therapy for Therapeutic Angiogenesis, Gene Therapy - Developments and
Future Perspectives, Prof. Chunsheng Kang (Ed.), ISBN: 978-953-307-617-1, InTech, Available from:
http://www.intechopen.com/books/gene-therapy-developments-and-future-perspectives/gene-therapy-for-
therapeutic-angiogenesis
© 2011 The Author(s). Licensee IntechOpen. This chapter is distributed
under the terms of the Creative Commons Attribution-NonCommercial-
ShareAlike-3.0 License, which permits use, distribution and reproduction for
non-commercial purposes, provided the original is properly cited and
derivative works building on this content are distributed under the same
license.
